

primary studies - published RCT

A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.

Code: PM17536872

Year: 2007 **Date:** 2011

Author: Chuchalin A

Study design (if review, criteria of inclusion for studies)

randomized, placebo-controlled multicenter trial

Participants

260 children and adolescents with CF. The study enrolled relatively healthy children and adolescents with CF but uninfected with *P. aeruginosa*

Interventions

Respiratory tract specimens were obtained at baseline, day 84, and day 168

Outcome measures

azithromycin

Main results

At baseline, 74% of both azithromycin and placebo participants harbored *S. aureus* (3) and 4.6% of participants harbored SCV *S. aureus*. There was no association between treatment with azithromycin and emergence of SCV *S. aureus*. Treatment-emergent azithromycin-resistant non-SCV strains of methicillin-susceptible and/or methicillin-resistant *S. aureus* were detected in 37% of azithromycin and 11% of placebo participants (P

Authors' conclusions

despite treatment-emergent azithromycin-resistant *S. aureus*, long-term treatment with azithromycin among children and adolescents with CF, most of whom were infected with *S. aureus* at baseline, was not associated with treatment-emergent SCV strains

<http://dx.doi.org/10.2165/00148581-200709001-00004>

See also

Paediatr Drugs. 2007;9 Suppl 1:21-31.

Keywords

Bacterial Infections; Immunoregulatory; Infection; pharmacological_intervention; Respiratory Tract Diseases; Respiratory Tract Infections; Staphylococcus aureus; Azithromycin; Anti-Bacterial Agents; Macrolides; Anti-Inflammatory Agents; Anti-Inflammatory Agents - excl Steroids;